CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with cancer.
  
  LEARNING OBJECTIVES

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers, and refer appropriate patients for study participation.
  • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

  ACCREDITATION STATEMENTS
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CME CREDIT DESIGNATION STATEMENTS
  Audio Program: Research To Practice designates this enduring material for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  NCPD CREDIT DESIGNATION STATEMENTS
  Audio Program: This educational activity for 7.75 contact hours is provided by RTP during the period of December 2020 through December 2021.
  
  This activity is awarded 7.75 ANCC pharmacotherapeutic contact hours.
  
  Video Program: This educational activity for 7.25 contact hours is provided by RTP during the period of December 2020 through December 2021.
  
  This activity is awarded 7.25 ANCC pharmacotherapeutic contact hours.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 7.75 (audio) and 7.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/FCSSummit20/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/FCSSummit20/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/FCSSummit20/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/FCSSummit20/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/FCSSummit20.
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the mp3s, review the downloadable slide set, complete the Post-test with a score of 80% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/FCSSummit20/CNE. The corresponding video program is available as an alternative at ResearchToPractice.com/FCSSummit20/Video.
  
  Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/FCSSummit20/Video/CNE. The corresponding audio program is available as an alternative at ResearchToPractice.com/FCSSummit20.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME and NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Arjun Balar, MD
  Associate Professor, Department of Medicine
  Director, Genitourinary Medical Oncology Program
  NYU Perlmutter Cancer Center
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Nektar, Pfizer Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Immunomedics Inc, Janssen Biotech Inc, Merck, Nektar, Pfizer Inc, Seagen Inc.
  
  Johanna Bendell, MD
  Chief Development Officer
  Director, Drug Development Unit Nashville
  Sarah Cannon Research Institute
  Tennessee Oncology
  Nashville, Tennessee
  
  Advisory Committee and Consulting Agreements (To Institution): Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma Inc, a subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna Inc, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Piper Biotech, Prelude Therapeutics, Relay Therapeutics, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc, Torque Therapeutics, Translational Drug Development; Research Funding to Institution: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, Array BioPharma Inc, a subsidiary of Kyn Therapeutics, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, Bayer HealthCare Pharmaceuticals, Beigene, Bellicum Pharmaceuticals Inc, Bicycle Therapeutics, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, CALGB, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Cyteir Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Kolltan Pharmaceutical Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Morphotek Inc, Nektar, NGM Biopharmaceuticals, Novartis, Novocure, Numab Therapeutics, OncoGenex Pharmaceuticals Inc, Oncologie, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, Relay Therapeutics, Revolution Medicines, Rgenix, Sanofi Genzyme, Scholar Rock, Seagen Inc, Shattuck Labs, Sierra Oncology, Stemcentrx, Sumitomo Dainippon Pharma Oncology Inc, SynDevRx Inc, Synthorx, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics Inc, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Tyrogenex Inc, Unum Therapeutics, Vyriad, Zymeworks.
  
  Axel Grothey, MD
  Director, GI Cancer Research
  West Cancer Center and Research Institute
  Chair, OneOncology Research Network
  OneOncology
  Germantown, Tennessee
  
  Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Taiho Oncology Inc, Takeda Oncology; Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: Regeneron Pharmaceuticals Inc.
  
  Brad S Kahl, MD
  Professor of Medicine
  Washington University School of Medicine
  Director, Lymphoma Program
  Siteman Cancer Center
  St Louis, Missouri
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP; Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, BeiGene, Celgene Corporation, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Celgene Corporation.
  
  Shaji K Kumar, MD
  Mark and Judy Mullins Professor of Hematological Malignancies
  Consultant, Division of Hematology
  Professor of Medicine
  Mayo Clinic
  Rochester, Minnesota
  
  Advisory Committee: AbbVie Inc, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Takeda Oncology; Consulting Agreements: AbbVie Inc, Amgen Inc, Celgene Corporation, Cellectar Biosciences Inc, GeneCentrix Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Molecular Partners, Oncopeptides, Takeda Oncology; Contracted Research: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CARsgen Therapeutics, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Oncology, TeneoBio.
  
  Kathleen Moore, MD
  The Virginia Kerley Cade Endowed Chair in Cancer Development
  Associate Director, Clinical Research
  Director, Oklahoma TSET Phase I Program
  Stephenson Cancer Center
  Associate Professor, Section of Gynecologic Oncology
  Director, Gynecologic Oncology Fellowship
  Department of Obstetrics and Gynecology
  University of Oklahoma Health Sciences Center
  Oklahoma City, Oklahoma
  
  Advisory Committee: AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, ImmunoGen Inc, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Tarveda Therapeutics, Tesaro, A GSK Company, Vavotar Life Sciences; Consulting Agreement: Akesobio; Contracted Research: Lilly, Merck, PTC Therapeutics, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: Incyte Corporation; Employment: GOG Foundation/Partners, NRG Oncology.
  
  Loretta Nastoupil, MD
  Associate Professor
  Department of Lymphoma/Myeloma
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gamida Cell, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Novartis, Pfizer Inc; Contracted Research: Celgene Corporation, Epizyme, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma.
  
  William K Oh, MD
  Chief, Division of Hematology and Medical Oncology
  Professor of Medicine and Urology
  Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
  Icahn School of Medicine at Mount Sinai
  Associate Director of Clinical Research
  The Tisch Cancer Institute
  Mount Sinai Health System
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CPS Companion Diagnostics, Janssen Biotech Inc, Sanofi Genzyme, Sema4, TeneoBio.
  
  David M O'Malley, MD
  Professor
  Division Director, Gynecologic Oncology
  Co-Director, Gynecologic Oncology Phase I Program
  The Ohio State University and The James Cancer Center
  Columbus, Ohio
  
  Advisory Committee: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genelux, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Merck, Myriad Genetic Laboratories Inc, Novocure, Regeneron Pharmaceuticals Inc, Tarveda Therapeutics, Tesaro, A GSK Company; Consulting Agreements: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Novocure, Regeneron Pharmaceuticals Inc, Seagen Inc, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, New Mexico Cancer Care Alliance, Novocure, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seagen Inc, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Marker Therapeutics Inc.
  
  Robert Z Orlowski, MD, PhD
  Florence Maude Thomas Cancer Research Professor
  Department of Lymphoma and Myeloma
  Professor, Department of Experimental Therapeutics
  Director, Myeloma Section
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, EcoR1 Capital LLC, FORMA Therapeutics, Genzyme Corporation, GlaxoSmithKline, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech, Molecular Partners, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier, Takeda Pharmaceuticals North America Inc; Consulting Agreement: STATinMED; Contracted Research: BioTheryX Inc, CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals North America Inc; Ownership Interest: Asylia Therapeutics Inc (founder, patents, equity).
  
  Hope S Rugo, MD
  Professor of Medicine
  Director, Breast Oncology and Clinical Trials Education
  University of California, San Francisco
  Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  Consulting Agreements: Puma Biotechnology Inc, Samsung Bioepis; Contracted Research: Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seagen Inc; Paid Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan NV, Novartis, Pfizer Inc.
  
  Gregory J Riely, MD, PhD
  Associate Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committee and Consulting Agreements: Daiichi Sankyo Inc, Takeda Oncology; Contracted Research: Merck, Mirati Therapeutics, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology.
  
  David R Spigel, MD
  Chief Scientific Officer
  Program Director, Lung Cancer Research
  Sarah Cannon Research Institute
  Nashville, Tennessee
  
  Consulting Agreements: Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Dracen Pharmaceuticals, EMD Serono Inc, Evelo Biosciences Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Iksuda Therapeutics, Illumina, Merck, Molecular Templates, Nektar, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceutical Company Limited, Triptych Health Partners, TRM Oncology; Contracted Research: Aeglea BioTherapeutics, Astellas, AstraZeneca Pharmaceuticals LP, BIND Therapeutics Inc, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, G1 Therapeutics, Genentech, a member of the Roche Group, Grail Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Molecular Partners, Nektar, Neon Therapeutics, Novartis, Takeda Oncology, Transgene, UT Southwestern Medical Center.
  
  Sara M Tolaney, MD, MPH
  Associate Director, Susan F Smith Center for Women’s Cancers
  Director of Clinical Trials, Breast Oncology
  Director of Breast Immunotherapy Clinical Research
  Senior Physician
  Breast Oncology Program
  Dana-Farber Cancer Institute
  Assistant Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Athenex, Bristol-Myers Squibb Company, Celldex Therapeutics, Eisai Inc, G1 Therapeutics, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, OncoPep, Paxman, Pfizer Inc, Puma Biotechnology Inc, Sanofi Genzyme, Seagen Inc, Silverback Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, Pfizer Inc, Sanofi Genzyme, Seagen Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME/NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Adaptive Biotechnologies Corporation, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Pharmacylics LLC, an AbbVie Company, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Merck, Novartis, Puma Biotechnology Inc, Sanofi Genzyme, Seagen Inc, Taiho Oncology Inc, and Takeda Oncology.
  
  Release date: December 2020
  Expiration date: December 2021
  
  After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.